XARELTO®: Dosing for stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)

ONCE-DAILY DOSING*
WITH 24-HOUR STROKE RISK REDUCTION1,2

ONCE-DAILY DOSING* WITH 24-HOUR STROKE RISK REDUCTION1,2

*Taken with evening meal.

No dose adjustment based on weight

20 mg

Once daily with the evening meal in patients with CrCl >50 mL/min

15 mg

MODERATE TO SEVERE RENAL IMPAIRMENT DOSE


Once daily with the evening meal in patients with CrCl ≤50 mL/min

Renal Dosing Considerations

  • Adjust XARELTO® dose based on renal function
  • Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly
  • Consider dose adjustment or discontinuation of XARELTO® in patients who develop acute renal failure while taking XARELTO®
  • See sections 2.1 and 8.6 of the Prescribing Information for additional information

Switch and Management

XARELTO® Dosing: All Indications

CrCl = creatinine clearance.

Previous: NVAF Safety Profile

References: 1. Patel MR, Mahaffey KW, Garg J, et al; and the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. 2. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421.